摘要
DNA损伤修复能够使肿瘤细胞耐受化疗药物造成的DNA损伤而存活,因此,调节某种特殊的DNA修复路径可以增强化疗药物的疗效。另外,有些DNA修复路径在一些肿瘤细胞中是失活的。目前,以DNA修复蛋白O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)和错配修复蛋白作为调节靶标,提高化疗效果的联合用药策略正在进行各期临床实验。靶向DNA修复机制增强抗肿瘤化疗药物的疗效、克服肿瘤耐药正成为肿瘤个体化化疗研究的一个重要领域。
DNA repair pathways can enable tumor cells to survive DNA damage induced by anti-tumor drugs such as alkylating agents. Therefore, modulating specific DNA repair pathways might prove efficacious when used in combination with DNA-damaging chemotherapeutic drugs. In addition, some of these pathways were inactivated in certain cancers. Modulation of O^6-methylguanine-DNA methyhransferase（MGMT） and mismatch repair（MMR） expression in tumors and normal tissue is currently being investigated as a possible strategy for improving cancer therapy. Improving the efficacy of standard chemotherapy and surmounting chemotherapeutic alkylating drug resistance by targeting DNA repair mechanisms is becoming an important area in cancer research.
出处
《军事医学科学院院刊》
CSCD
北大核心
2009年第1期77-80,共4页
Bulletin of the Academy of Military Medical Sciences
